Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.
Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.
Rapid Micro Biosystems (Nasdaq: RPID) announced it will release its financial results for Q2 2021 after market close on August 26, 2021. The company will hold a webcast conference call at 1:30 PM PT/4:30 PM ET on the same day to discuss the results.
Rapid Micro Biosystems specializes in automation solutions for the manufacturing of healthcare products, enhancing quality control processes. Their flagship Growth Direct® platform modernizes microbial quality control in pharmaceutical manufacturing, ensuring faster, safer releases of products.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) announced the exercise of an over-allotment option from its initial public offering, resulting in the sale of 1,086,604 additional shares at $20.00 each, generating gross proceeds of $21.7 million. This transaction closed on August 4, 2021. The offering was managed by J.P. Morgan, Morgan Stanley, Cowen, and Stifel. The registration statement for this offering became effective on July 14, 2021, and details can be accessed through the designated underwriters.
Rapid Micro Biosystems (Nasdaq: RPID) has appointed Melinda Litherland to its board of directors as of June 2021. Litherland, a CPA with over 30 years in audit experience, brings significant expertise in the Technology and Life Sciences sectors from her tenure at Deloitte. The company aims to leverage her financial acumen to address complex accounting challenges while pursuing its goal of becoming a leader in microbial quality control. Rapid Micro specializes in automation solutions for the healthcare industry, including the innovative Growth Direct® platform, enhancing operational efficiency and compliance in pharmaceutical manufacturing.
Rapid Micro Biosystems announced the pricing of its initial public offering (IPO) of 7,920,000 shares of Class A common stock at $20.00 per share, aiming to raise $158.4 million before expenses. The shares will trade on the Nasdaq under the symbol RPID starting July 15, 2021, with the offering expected to close on July 19, 2021. Underwriters have a 30-day option to purchase an additional 1,188,000 shares. The company focuses on automation solutions for healthcare product manufacturing.